The newly updated Oncology Medical Home (OMH) Standards, published July 21 in JCO Oncology Practice, introduce four new standards and incorporates two modifications to existing standards.

After a fast-paced 2025 legislative session, in which all 50 states and Washington, D.C., convened, most legislatures have adjourned for the year. While several states entered the session with ...

The 2025 American Medical Association (AMA) House of Delegates (HOD) Annual Meeting, held in Chicago from June 6-11, was a key platform for ASCO's delegation to engage in robust discussions and ...

While federal prior authorization reform legislation has yet to make it over the finish line and be enacted into law, state governments continue to pass legislation to mitigate the burdensome ...

A REMS letter for health care providershas been released to address the potential risk of severe hypocalcemia in patients with advanced chronic kidney disease following Jubbonti administration. More ...

CHICAGO — Results from the international phase 3 AMPLITUDE clinical trial found that adding niraparib to abiraterone acetate (AKEEGA™) plus prednisone (AAP) can help slow cancer growth for people with ...

CHICAGO — Results from the phase 3 DESTINY-Breast09 clinical trial found that the combination of trastuzumab deruxtecan (Enhertu®) with pertuzumab (Perjeta®) can delay cancer growth for longer than ...

“This is the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer to demonstrate that post-treatment exercise is both achievable and effective in improving ...

“The pace of therapeutic advances in upper gastrointestinal cancers has accelerated in recent years. Now, the MATTERHORN trial shows that perioperative treatment with FLOT plus durvalumab is better ...

Recent studies have found that anti-inflammatory medications like aspirin can reduce the risk of developing colorectal cancer and cancer recurrence for certain subsets of patients with stage III colon ...

Switching to Camizestrant After Detection of an ESR1 Mutation Improves Progression-Free Survival for Some Patients With Advanced Breast Cancer ...

“This study will change the standard of care for the subset of patients with deficient DNA mismatch repair colon cancer by incorporating atezolizumab to standard of care FOLFOX chemotherapy in the ...